Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors [Seeking Alpha]
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: Seeking Alpha
Follow Summary Zynrelef, a combination of bupivacaine and meloxicam, was FDA-approved in 2021 for postoperative pain management, offering a non-opioid alternative. The recent label expansion and inclusion in the NOPAIN Act may support wider Zynrelef adoption, though actual sales remain modest. Concerns about NSAID safety in surgeries, especially related to impaired tissue healing, might limit Zynrelef's acceptance despite its clinical benefits. Heron has improved its financial health, reducing net losses and maintaining a cash runway into late 2026, but financial risks remain significant. While Zynrelef shows promise, its tepid sales, niche market, and financial challenges lead to a "sell" recommendation, as it's unlikely to drive significant growth. Morsa Images/DigitalVision via Getty Images Heron Therapeutics: Smoothing Out the Kinks in Pain Management? Heron Therapeutics NASDAQ: HRTX ) markets niche products for oncology and acute care. Heron Zynrelef , a co
Show less
Read more
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics, Inc. (NASDAQ: HRTX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Heron Therapeutics, Inc. (NASDAQ: HRTX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Heron Therapeutics, Inc. (NASDAQ: HRTX) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ... [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]Yahoo! Finance
HRTX
Earnings
- 11/12/24 - In-Line
HRTX
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- HRTX's page on the SEC website